Modulation of B-cell receptor and microenvironment signaling by a guanine exchange factor in B-cell malignancies

被引:3
|
作者
Liao, Wei [1 ]
Sharma, Sanjai [1 ]
机构
[1] UCLA Sch Med, Greater Los Angeles VA Healthcare Ctr, Div Hematol Oncol, Los Angeles, CA USA
关键词
CHRONIC LYMPHOCYTIC-LEUKEMIA; TYROSINE KINASE; BONE-MARROW; THERAPEUTIC TARGET; DOWN-REGULATION; EXPRESSION; ZAP-70; APOPTOSIS; OVEREXPRESSION; ERK;
D O I
10.20892/j.issn.2095-3941.2016.0026
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) cells over-express a guanine exchange factor (GEF), Rasgrf-1. This GEF increases active Ras as it catalyzes the removal of GDP from Ras so that GTP can bind and activate Ras. This study aims to study the mechanism of action of Rasgrf-1 in B-cell malignancies. Methods: N-terminus truncated Rasgrf-1 variants have a higher GEF activity as compared to the full-length transcript therefore a MCL cell line with stable over-expression of truncated Rasgrf-1 was established. The B-cell receptor (BCR) and chemokine signaling pathways were compared in the Rasgrf-1 over-expressing and a control transfected cell line. Results: Cells over-expressing truncated form of Rasgrf-1 have a higher proliferative rate as compared to control transfected cells. BCR was activated by lower concentrations of anti-IgM antibody in Rasgrf-1 over-expressing cells as compared to control cells indicating that these cells are more sensitive to BCR signaling. BCR signaling also phosphorylates Rasgrf-1 that further increases its GEF function and amplifies BCR signaling. This activation of Rasgrf-1 in over-expressing cells resulted in a higher expression of phospho-ERK, AKT, BTK and PKC-alpha as compared to control cells. Besides BCR, Rasgrf-1 over-expressing cells were also more sensitive to microenvironment stimuli as determined by resistance to apoptosis, chemotaxis and ERK pathway activation. Conclusions: This GEF protein sensitizes B-cells to BCR and chemokine mediated signaling and also upregulates a number of other signaling pathways which promotes growth and survival of these cells.
引用
收藏
页码:277 / 285
页数:9
相关论文
共 50 条
  • [41] The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies
    Shain, K. H.
    Tao, J.
    ONCOGENE, 2014, 33 (32) : 4107 - 4113
  • [42] Antigen-Independent, Autonomous B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma
    Eken, Janneke A.
    Koning, Marvyn T.
    Yanez, Julieta H. Sepulveda
    van Bergen, Cornelis A. M.
    Quinten, Edwin
    Kupcova, Kristyna
    Havranek, Ondrej
    De Groen, Ruben A. L.
    Vermaat, Joost S. P.
    de Jong, Daphne
    Kluin, Philip
    Cleven, Arjen
    Jumaa, Hassan
    Veelken, Hendrik
    BLOOD, 2022, 140 : 6444 - 6445
  • [43] Early B-cell factor 'pioneers' the way for B-cell development
    Hagman, J
    Lukin, K
    TRENDS IN IMMUNOLOGY, 2005, 26 (09) : 455 - 461
  • [44] The Interplay between MicroRNAs and the Components of the Tumor Microenvironment in B-Cell Malignancies
    El-Daly, Sherien M.
    Bayraktar, Recep
    Anfossi, Simone
    Calin, George A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (09)
  • [45] The microenvironment in mature B-cell malignancies: a target for new treatment strategies
    Burger, Jan A.
    Ghia, Paolo
    Rosenwald, Andreas
    Caligaris-Cappio, Federico
    BLOOD, 2009, 114 (16) : 3367 - 3375
  • [46] MONOCLONAL ANTI B-CELL REAGENTS IN THE DELINEATION OF SUBSETS IN HUMAN B-CELL MALIGNANCIES
    HERRMANN, F
    KOMISCHKE, B
    LUDWIG, WD
    KOLECKI, P
    SIEBER, G
    RUHL, H
    IMMUNOBIOLOGY, 1983, 165 (3-4) : 277 - 277
  • [47] B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma: Tonic Alone in the Germinal Center B-Cell Subtype, Plus Self Antigen-Induced in the Activated B-Cell Subtype
    Havranek, Ondrej
    Koehrer, Stefan
    Xu, Jingda
    Becker, Lisa
    Comer, Justin M.
    Karri, Anusha R.
    Wang, Zhiqiang
    Ma, Wencai
    Westin, Jason R.
    Zal, Tomasz
    Burger, Jan A.
    Davis, R. Eric
    BLOOD, 2015, 126 (23)
  • [48] Somatic hypermutation and B-cell malignancies
    Spencer, J
    Dunn-Walters, DK
    JOURNAL OF PATHOLOGY, 1999, 187 (02): : 158 - 163
  • [49] Lenalidomide for the treatment of B-cell malignancies
    Chanan-Khan, Asher A.
    Cheson, Bruce D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) : 1544 - 1552
  • [50] Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment
    Young, Ryan M.
    Phelan, Mes D.
    Wilson, Wyndham H.
    Staudt, Louis M.
    IMMUNOLOGICAL REVIEWS, 2019, 291 (01) : 190 - 213